Stock Track | MannKind Shares Plummet 6.75% Pre-market on Discontinuation of Key Phase 3 Trial

Stock Track

Nov 10, 2025

MannKind Corporation (MNKD) saw its shares tumble 6.75% in pre-market trading on Monday, following the announcement of a significant setback in one of its clinical trials. The biopharmaceutical company, known for its innovative drug delivery technologies, has decided to discontinue its ICON-1 Phase 3 clinical trial for nebulized clofazimine, a potential treatment for NTM (Nontuberculous Mycobacterial) lung disease.

The decision to halt the trial came after an independent Data Safety Monitoring Board (DSMB) recommended discontinuation due to futility. This means that the trial was unlikely to meet its primary efficacy endpoints, even if it had been carried through to completion. The news has dealt a blow to MannKind's pipeline and near-term growth prospects, leading to the sharp decline in investor confidence reflected in the pre-market stock movement.

Despite this setback, MannKind stated that the development of MNKD-102 remains under consideration. However, the discontinuation of the ICON-1 trial is likely to have a significant impact on the company's research and development strategy moving forward. Investors will be closely watching for any updates on MannKind's pipeline and how the company plans to allocate its resources in the wake of this clinical trial failure.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1106472140"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1106472140\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1106472140?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 21:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106472140","market":"nz","top_or_hot":-1,"title":"Stock Track | MannKind Shares Plummet 6.75% Pre-market on Discontinuation of Key Phase 3 Trial","media":"Stock Track","content":"<p>MannKind Corporation (MNKD) saw its shares tumble 6.75% in pre-market trading on Monday, following the announcement of a significant setback in one of its clinical trials. The biopharmaceutical company, known for its innovative drug delivery technologies, has decided to discontinue its ICON-1 Phase 3 clinical trial for nebulized clofazimine, a potential treatment for NTM (Nontuberculous Mycobacterial) lung disease.</p>\n\n<p>The decision to halt the trial came after an independent Data Safety Monitoring Board (DSMB) recommended discontinuation due to futility. This means that the trial was unlikely to meet its primary efficacy endpoints, even if it had been carried through to completion. The news has dealt a blow to MannKind's pipeline and near-term growth prospects, leading to the sharp decline in investor confidence reflected in the pre-market stock movement.</p>\n\n<p>Despite this setback, MannKind stated that the development of MNKD-102 remains under consideration. However, the discontinuation of the ICON-1 trial is likely to have a significant impact on the company's research and development strategy moving forward. Investors will be closely watching for any updates on MannKind's pipeline and how the company plans to allocate its resources in the wake of this clinical trial failure.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | MannKind Shares Plummet 6.75% Pre-market on Discontinuation of Key Phase 3 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | MannKind Shares Plummet 6.75% Pre-market on Discontinuation of Key Phase 3 Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-10 21:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>MannKind Corporation (MNKD) saw its shares tumble 6.75% in pre-market trading on Monday, following the announcement of a significant setback in one of its clinical trials. The biopharmaceutical company, known for its innovative drug delivery technologies, has decided to discontinue its ICON-1 Phase 3 clinical trial for nebulized clofazimine, a potential treatment for NTM (Nontuberculous Mycobacterial) lung disease.</p>\n\n<p>The decision to halt the trial came after an independent Data Safety Monitoring Board (DSMB) recommended discontinuation due to futility. This means that the trial was unlikely to meet its primary efficacy endpoints, even if it had been carried through to completion. The news has dealt a blow to MannKind's pipeline and near-term growth prospects, leading to the sharp decline in investor confidence reflected in the pre-market stock movement.</p>\n\n<p>Despite this setback, MannKind stated that the development of MNKD-102 remains under consideration. However, the discontinuation of the ICON-1 trial is likely to have a significant impact on the company's research and development strategy moving forward. Investors will be closely watching for any updates on MannKind's pipeline and how the company plans to allocate its resources in the wake of this clinical trial failure.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MNKD","symbol_name":"曼恩凯德生物医疗","start_time":0,"source_url":"","article_id":"1106472140","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106472140","pubTimestamp":1762779890,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"MannKind Corporation (MNKD) saw its shares tumble 6.75% in pre-market trading on Monday, following the announcement of a significant setback in one of its clinical trials. The biopharmaceutical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MNKD":"曼恩凯德生物医疗"},"translate_title":"股票追踪|关键3期试验终止MannKind股价盘前暴跌6.75%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNKD":1},"content_text":"MannKind Corporation (MNKD) saw its shares tumble 6.75% in pre-market trading on Monday, following the announcement of a significant setback in one of its clinical trials. The biopharmaceutical company, known for its innovative drug delivery technologies, has decided to discontinue its ICON-1 Phase 3 clinical trial for nebulized clofazimine, a potential treatment for NTM (Nontuberculous Mycobacterial) lung disease.\nThe decision to halt the trial came after an independent Data Safety Monitoring Board (DSMB) recommended discontinuation due to futility. This means that the trial was unlikely to meet its primary efficacy endpoints, even if it had been carried through to completion. The news has dealt a blow to MannKind's pipeline and near-term growth prospects, leading to the sharp decline in investor confidence reflected in the pre-market stock movement.\nDespite this setback, MannKind stated that the development of MNKD-102 remains under consideration. However, the discontinuation of the ICON-1 trial is likely to have a significant impact on the company's research and development strategy moving forward. Investors will be closely watching for any updates on MannKind's pipeline and how the company plans to allocate its resources in the wake of this clinical trial failure.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}